Shareholders that lost money on Skye Bioscience, Inc.(SKYE) should contact The Gross Law Firm about pending Class Action - SKYE

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Skye Bioscience, Inc. regarding a class action lawsuit due to allegations of misleading statements related to the company's lead product candidate, nimacimab [1][2]. Group 1: Allegations and Class Period - The class period for the allegations is from November 4, 2024, to October 3, 2025 [1]. - Allegations include that the effectiveness of nimacimab was overstated, leading to inflated clinical, regulatory, and commercial prospects [1]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action by January 16, 2026, to potentially become lead plaintiffs [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle [2]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [3].